STIMHealthcare · Medical DevicesThe 3 Wall Street analysts covering Neuronetics, Inc. hold a median 12-month price target of $6 — +100.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 63 of 100 as at 22 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Neuronetics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (98): Sales and profits are climbing, and climbing faster than before.
Volatility (9): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on STIM, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +100.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 11 Aug 2026 | BTIG | Maintains | Buy | $5.00 → $6.00 |
| 20 July 2026 | BTIG | Initiates | Buy | — |
| 20 July 2026 | BTIG | Initiates | Buy | $5.00 |
| 19 Mar 2026 | Canaccord Genuity | Maintains | Buy | $7.00 → $3.00 |
| 19 Mar 2026 | Canaccord Genuity | Maintains | Buy | — |
| 6 Aug 2025 | Canaccord Genuity | Maintains | Buy | — |
| 5 Mar 2025 | Canaccord Genuity | Maintains | Buy | — |
| 5 Mar 2025 | Citizens Capital Markets | Maintains | Market Outperform | — |
| 14 Aug 2024 | JMP Securities | Maintains | Market Outperform | — |
| 13 Aug 2024 | Canaccord Genuity | Maintains | Buy | — |
| 12 Aug 2024 | William Blair | Downgrade | Market Perform | — |
| 14 May 2024 | William Blair | Upgrade | Outperform | — |
| 6 Mar 2024 | Piper Sandler | Reiterates | Overweight | — |
| 10 May 2023 | JMP Securities | Reiterates | Market Outperform | — |
| 8 Mar 2023 | Canaccord Genuity | Maintains | Buy | — |
| 8 Mar 2023 | JMP Securities | Reiterates | Market Outperform | — |
| 14 Oct 2021 | JMP Securities | Maintains | Market Outperform | — |
| 13 Oct 2021 | BTIG | Downgrade | Neutral | — |
| 22 Jan 2021 | William Blair | Upgrade | Outperform | — |
| 26 Oct 2020 | Canaccord Genuity | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. STIM appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 90% of US stocks
Cheaper than 60% of US stocks
Cheaper than 8% of US stocks
Cheaper than 87% of US stocks
Higher than 50% of US stocks
Higher than 45% of US stocks
Higher than 59% of US stocks
Higher than 29% of US stocks
Higher than 16% of US stocks
Higher than 11% of US stocks
Higher than 26% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Neuronetics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Neuronetics, Inc. published its Q2 2026 earnings call transcript on Seeking Alpha, covering the company's second-quarter financial results and management discussion.
Why it matters — A STIM watcher would care because the transcript provides the company's official quarterly update, including its financial performance and commentary.
Neuronetics reported second-quarter 2026 revenue growth, a sharply narrower net loss, and positive adjusted EBITDA, driven by expansion of its Greenbrook clinic business and new commercial purchasing options for its NeuroStar TMS systems.
Why it matters — The financial results show improved operational performance and growing adoption of the company's core TMS therapy platform.
Neuronetics (STIM) reported a second-quarter loss of $0.05 per share, which was narrower than the Zacks Consensus Estimate of a $0.11 loss and an improvement from a $0.15 per share loss in the prior-year quarter.
Why it matters — A smaller-than-expected quarterly loss indicates improved financial performance versus analyst expectations and the year-ago period, which STIM watchers would track closely.
Neuronetics and Jorey Chernett — its second-largest shareholder and Managing Member of Pointillist Family Office — announced they have created a constructive framework, called the "Understanding," for alignment between the Company's Board, management, and Mr. Chernett.
Why it matters — Because Mr. Chernett is the Company's second-largest shareholder, this announced framework for board-management-shareholder alignment is directly relevant to STIM watchers following governance and shareholder relations.
Neuronetics announced the granting of inducement awards to five new non-executive employees under Nasdaq Listing Rule 5635(c)(4).
Why it matters — The disclosure signals the company is hiring new staff, and the inducement grants provide insight into how Neuronetics attracts and compensates talent.
The 3 Wall Street analysts covering Neuronetics, Inc. have a median 12-month price target of $6, with estimates ranging from $5 to $7. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering Neuronetics, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Neuronetics, Inc. 63 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Neuronetics, Inc. ranks 63 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (98 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +100.0% from the last close, and Ticker Nerd's factor model ranks Neuronetics, Inc. 63 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Neuronetics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for STIM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $7 over the next 12 months.
Neuronetics, Inc. returned -11.2% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Neuronetics Inc. is a commercial stage medical technology and healthcare company focused on designing, developing, and marketing products that improve the quality of life for patients suffering from neurohealth and psychiatric disorders.
The most recent item we track (Seeking Alpha, 11 Aug 2026): "Neuronetics, Inc. (STIM) Q2 2026 Earnings Call Transcript". Neuronetics, Inc. published its Q2 2026 earnings call transcript on Seeking Alpha, covering the company's second-quarter financial results and management discussion.
Neuronetics Inc. is a commercial stage medical technology and healthcare company focused on designing, developing, and marketing products that improve the quality of life for patients suffering from neurohealth and psychiatric disorders. Its primary offering is the NeuroStar Advanced Therapy System, a non-drug, noninvasive transcranial magnetic stimulation (TMS) treatment delivered in office-based settings. This system generates pulsed, MRI-strength magnetic fields to stimulate specific brain areas associated with mood, serving as a therapeutic alternative for adults and adolescents aged 15-21 with major depressive disorder (MDD) when medications prove inadequate. Neuronetics Inc. operates a vertically integrated model that includes manufacturing and selling NeuroStar systems and treatment sessions, alongside owning and managing Greenbrook TMS Inc. treatment centers across the United States. These centers provide NeuroStar Advanced Therapy, along with other modalities like SPRAVATO for MDD and related conditions. The company engages with health policy stakeholders and payors to support coverage and reimbursement for TMS therapies, positioning itself as a leader in evidence-based, device-driven mental health solutions. Founded in 1998 and headquartered in Malvern, Pennsylvania, Neuronetics Inc. emphasizes expanding access to advanced neurohealth treatments through its direct sales, customer support, and clinical outcomes registry.
CEO Mr. Daniel L. Reuvers · 658 employees · United States · https://neurostar.com/neuronetics